Stockreport

Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019

Immunovant, Inc.  (IMVT) 
PDF Ended quarter with $123.5 million in cashReceived IND clearance to initiate Phase 2a trial in warm autoimmune hemolytic anemia (WAIHA) NEW YORK, Feb. 14, 2020 (GLOBE [Read more]